Allogeneic haematopoietic stem-cell transplantation demonstrates that transplantation of haematopoietic stem cells (HSCs) with only a single wild-type HBB gene can cure the β -haemoglobinopathies. However, this transplantation technique is limited because of graftversus-host disease and a lack of immunologically matched donors. An alternative to using allogeneic HSCs to cure the β -haemoglobinopathies is to use homologous recombination to modify the HBB gene directly in autologous HSCs 1, 2 . In 1985, Smithies and colleagues 3 were able to modify the human HBB gene by homologous recombination in a human embryonic carcinoma cell line, albeit at an extremely low frequency (10 −6 ). The subsequent discoveries that a site-specific DNA double-strand break (DSB) could stimulate homologousrecombination-mediated correction of a reporter gene and that engineered nucleases could be used to induce this DSB, formed the foundation of using homologous-recombination-mediated genome editing using engineered nucleases to modify the HBB gene directly 4, 5 . The ease of engineering as well as the robust activity of the CRISPR/ Cas9 RNA-guided endonuclease system makes it a promising tool to apply to the continuing challenge of developing effective and safe homologous-recombination-mediated genome editing to cure β -haemoglobinopathies 6, 7 . The CRISPR/Cas9 complex consists of the Cas9 endonuclease and a 100-nucleotide single-guide RNA (sgRNA). Target identification relies first on recognition of a 3-base-pair protospacer adjacent motif (PAM) and then on hybridization between a 20-nucleotide stretch of the sgRNA and the DNA target site, which triggers Cas9 to cleave both DNA strands 8 . DSB formation activates two highly conserved repair mechanisms: canonical non-homologous end-joining (NHEJ) and homologous recombination 9 . Through iterative cycles of break and NHEJ repair, insertions and/or deletions (INDELs) can be created at the site of the break. By contrast, genome editing by homologous recombination requires the delivery of a DNA donor molecule to serve as a homologous template, which the cellular recombination machinery uses to repair the break by a 'copy and paste' method 10 . For gene-editing purposes, the homologous recombination pathway can be exploited to make precise nucleotide changes in the genome 4 . One of the key features of precise genome editing, in contrast to viral-vectorbased gene transfer methods, is that endogenous promoters, regulatory elements, and enhancers can be preserved to mediate spatiotemporal gene expression 1, [11] [12] [13] . The CRISPR/Cas9 system is highly effective at stimulating DSBs in primary human haematopoietic stem and progenitor cells (HSPCs) when the sgRNA is synthesized with chemical modifications, and then electroporated into cells 14 .
HSCs have the ability to repopulate an entire haematopoietic system 15 , and several genetic [16] [17] [18] and acquired 19 diseases of the blood could potentially be cured by genome editing of HSCs. Recent studies have demonstrated efficient targeted integration in HSPCs by combining zinc-finger nuclease (ZFN) expression with exogenous homologous recombination donors delivered via single-stranded oligonucleotides 20 , integrase-defective lentiviral vectors 21 , or recombinant adeno-associated viral vectors of serotype 6 (rAAV6) 22, 23 . While showing very positive results in vitro, collectively, these studies also suggested that targeting HSCs by homologous recombination at disease-causing loci is difficult in clinically relevant HSPCs.
In this study, we achieve efficient homologous-recombinationmediated editing frequencies at the HBB locus in CD34 + HSPCs derived from mobilized peripheral blood using Cas9 ribonucleoproteins combined with rAAV6 homologous donor delivery. In brief, we demonstrate: (1) Cas9-and rAAV6-mediated HBB targeting in HSCs characterized by the identification of modified human cells in . Both platforms use sgRNAs chemically modified at both termini with 2′-O-methyl-3′-phosphorothioate, and are delivered either in conjunction with Cas9 mRNA or as a ribonucleoprotein (RNP) complex. Both platforms yielded high INDEL frequencies when electroporated into HSPCs, with the RNP showing higher activity (Fig. 1b) . By supplying ssAAV6 HBB donors after electroporation of Cas9 RNP, we achieved stable green fluorescent protein (GFP) expression in an average of 29% of HSPCs (Fig. 1c) . We observed lower efficiencies using the mRNA platform (15%) (Fig. 1c) . Cytotoxicity and off-target cleavage activity 14 was significantly decreased using the RNP system (Extended Data Fig. 1b-d) .
Because AAV genomes can be captured at the site of an off-target DSB via NHEJ 22,25,26 , we performed experiments mismatching a nuclease with a non-homologous donor to see whether this occurs with our methodology. While approximately 20% of cells that received matched HBB nuclease and HBB donor maintained GFP expression after 18 days in culture, IL2RG nuclease combined with HBB donor resulted in 0.8% GFP + cells (Extended Data Fig. 1e-g ), which was not significantly higher than the 0.5% GFP + cells observed when using the HBB AAV donor alone. These results demonstrate that capture of the HBB donor is an infrequent event using this system in human HSPCs. Furthermore, the observed GFP expression in 0.5% of HSPCs with the AAV donor alone suggests that random integration of rAAV6 is limited in human HSPCs. In fact, previous reports have shown AAV-mediated targeted integration without a DSB 27, 28 , and thus, these GFP + cells may be the result of on-target events.
SCD is caused by a single nucleotide mutation (A to T), which changes an amino acid (Glu6Val) at codon 6 of the HBB gene 29 . We created a 4.5-kb rAAV6 donor template that would introduce the Glu6Val mutation along with six other silent single nucleotide polymorphisms (SNPs) to prevent Cas9 re-cutting of homologous recombination alleles (Extended Data Fig. 2a-c) . Using this rAAV6 donor with Cas9 RNP delivery, we measured an average allelic modification frequency of 19% in six different HSPC donors (Fig. 1d) . These results confirm that the combined use of CRISPR with rAAV6 can precisely change the nucleotide at the position of the mutation that causes SCD.
Early enrichment of HBB-targeted HSPCs
Because HSCs differentiate and progressively lose their long-term repopulating capacity after culturing, the identification of gene-edited HSPCs early in the manufacturing process would be of great use. In experiments using a GFP-expressing rAAV6 donor we observed that while HSPCs receiving only the rAAV6 donor expressed low levels of GFP, HSPCs that also received Cas9 RNP generated a population at day 4 after electroporation that expressed much higher levels of GFP (Fig. 2a, left) . We proposed that this GFP high population was enriched for HBB-targeted cells. We therefore sorted and cultured the GFP high population as well as the GFP low and GFP − populations. While sorted GFP low and GFP − populations were, respectively, approximately 25% and 1% GFP + after 15-20 days in culture, the GFP high population was more than 95% GFP + , suggesting that this population was indeed HBBtargeted (Fig. 2a, right) . Linear regression showed that the percentage of GFP high -expressing HSPCs at day 4 after electroporation strongly correlates with the total percentage of GFP + cells at day 18 (Extended Data Fig. 3 ).
To confirm that the GFP high population was enriched for on-target integration, we used 'in-out PCR' (one primer binding the HBB locus outside the region of the homology arm and the other binding the integrated insert) to determine integration frequencies and allelic distribution in methylcellulose clones derived from the GFP high population (95 clones). A total of 92% of clones had a targeted integration, with 38% containing biallelic integrations (Fig. 2b, Extended Data  Fig. 4a-c and Supplementary Fig. 1a ). This assay generates colonies from progenitor cells and the biallelic integration frequency could be different in HSCs. Nonetheless, these data show that the log-fold + HSPCs. a, Schematic of targeted genome editing at the HBB locus using CRISPR/Cas9 and rAAV6. Site-specific DSBs are created by Cas9 (scissors) mainly between nucleotides 17 and 18 of the 20-bp target site, which is followed by the 5′ -NGG-3′ PAM sequence (red). A DSB stimulates homologous recombination (HR) using the rAAV6 homologous donor as a repair template. White boxes, HBB exons; blue boxes, homology arms; orange boxes, SFFV-GFP-polyA expression cassette. b, HSPCs were electroporated with mRNA or RNP CRISPR system, and INDELs were analysed via TIDE software (n = number of data points within each group, all from different mobilized peripheral blood or cord blood donors; * * P < 0.01, unpaired t-test. Bars represent means). c, HSPCs electroporated as above and transduced with HBB-specific rAAV6s were analysed by flow cytometry 18-21 days after electroporation when GFP levels were found to be constant. Left, percentage of GFP + HSPCs. Right, representative FACS plots (n = number of data points within each group, all from different donors; * * * P < 0.001, unpaired t-test. Bars represent means). d, HSPCs were treated as above but targeted with a rAAV6 Glu6Val donor. Frequencies of allele types were quantified by sequencing of a total of 600 clones from TOPO-cloned in-out PCRs (n = 6, all from different cord blood or bone marrow donors. Bars represent means). WT, wild type. 
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transgene expression shift after rAAV6 and RNP delivery is due to homologous recombination at the intended locus, and that the shift allows FACS-based enrichment of HBB-targeted HSPCs.
Although GFP is not a clinically relevant reporter gene, the truncated nerve growth factor receptor (tNGFR), in which the cytoplasmic intracellular signalling domain is removed, could be used to enrich for targeted HSPCs. tNGFR is expressed on the cell surface, thereby allowing antibody-mediated detection of gene marking, and has already been used in human clinical trials [30] [31] [32] [33] . We examined whether we could enrich HBB-targeted HSPCs using tNGFR magnetic-bead-based separation technology. HSPCs that received RNP and the rAAV6 donor (with a tNGFR expression cassette) produced a tNGFR high population that was not present in cells transduced with rAAV6 alone (Fig. 2c,  left) . We then enriched tNGFR high cells using anti-NGFR magnetic microbeads and after 18 days in culture, on average 84% of HSPCs were tNGFR + (Fig. 2c, right) . We then performed in-out PCR on tNGFR high methylcellulose clones to determine on-target integration frequencies, and found that 86% of clones had a targeted integration, with 30% having biallelic integrations (Fig. 2d , Extended Data Fig. 4d-f and Supplementary Fig. 1b ).
We next evaluated progenitor cell capacity of GFP high HSPCs using the colony-forming unit (CFU) assay. HBB GFP high HSPCs formed all types of colonies (erythroid, granulocyte/macrophage, and multilineage) to a comparable extent as mock-electroporated cells (Extended Data Fig. 5a-c) . We also evaluated frequencies of GFP high cells in subpopulations of HSPCs 15, [34] [35] [36] by immunophenotypic analysis, and observed a significant negative correlation between targeting frequencies and the immunophenotypic primitiveness of the analysed population (Extended Data Fig. 5d-f ). To confirm these findings, we used another strategy to evaluate targeting rates in the primitive HSC population. HSPCs or HSCs were sorted from fresh cord blood, then subjected to homologous recombination experiments, and we observed a 38% reduction in targeting efficiencies in the HSCs compared to the heterogeneous HSPC population (Extended Data Fig. 5g ). We next tested whether inefficient targeting of primitive cells could be due to reduced rAAV6 donor availability. HSCs and multipotent progenitors were transduced with scAAV6-SFFV-GFP, and results showed a fivefold reduction in the number of GFP + HSCs and multipotent progenitors compared to the bulk CD34 + population (Extended Data  Fig. 5h ). Collectively, our data suggest that although HSCs are more difficult to target than progenitor cells, we are achieving homologous recombination frequencies above 4% and usually above 10%.
HBB targeting in long-term repopulating HSCs
The current gold standard for HSC function, defined by the capacity to self-renew and form differentiated blood cells, is in vivo engraftment into immunodeficient non-obese diabetic (NOD)-severe combined immunodeficiency (SCID) Il2rg −/− (NSG) mice. We used HSPCs derived from mobilized peripheral blood for such studies because of their high clinical relevance, although these cells have been shown to have reduced engraftment capacity in NSG mice compared to HSPCs derived from fetal liver, cord blood and bone marrow 22, 37 . All transplanted mice displayed human engraftment in the bone marrow as measured by the presence of hCD45/HLA-ABC double-positive cells 16 weeks after transplant ( Fig. 3a and Extended Data Fig. 6a, b) . While we observed a decrease in human cell chimaerism for all treatment groups compared to the mock-treated group, all groups with nuclease-treated cells displayed similar chimaerism to the rAAV6-only group. We did measure a small, but not statistically significant, decrease for the RNP plus AAV GFP high group compared to RNP plus AAV, which can be explained by transplantation of fewer total cells and fewer phenotypically identified long-term HSCs (Extended Data  Fig. 6c ). There was a significant decrease from RNP plus AAV input targeting frequencies (16% in the CD34 + mobilized peripheral blood HSPCs) compared to the percentage of GFP + cells in the bone marrow at week 16 after transplantation (3.5%) (Fig. 3c ). This decrease is consistent with previous publications, and immunophenotyping of input cells did in fact show an average of 4% targeting in the CD34 Fig. 5f ). Despite these observed reductions in vivo, our median rates of HBB gene targeting in human cells in the bone marrow (3.5%) seem to be higher than what was found by others, particularly Hoban et al. and Genovese et al., in which most mice appeared to have less than 1% gene modification after transplant using ZFNs targeting HBB and IL2RG, respectively 20, 21 . By contrast, mice transplanted with RNP plus GFP high cells had a median of 90% GFP + human cells at week 16 after transplant, with three mice showing more than 97% GFP + human cells (Fig. 3a, c) . We also observed both myeloid (CD33 + ) and lymphoid (CD19 + ) reconstitution with a median of 94% and 83% GFP + cells, respectively (Fig. 3c) , implicating targeting of multipotent HSCs. We detected 5% and 49% GFP + human HSPCs (CD34 + CD10 − ) in the bone marrow of mice transplanted with RNP plus AAV and RNP plus AAV GFP high cells, respectively (Extended Data Fig. 7 ). Multi-parameter flow cytometric analysis showed no perturbations in lineage reconstitution and no evidence of abnormal haematopoiesis, a functional assessment of the safety of the editing procedure. To determine experimentally whether we targeted HBB in HSCs, we performed secondary transplants for the RNP plus AAV and RNP plus AAV GFP high groups. For both groups, we detected human cells in the bone marrow of secondary recipients at weeks 12-14 after transplant, with 7% and 90% GFP + cells for the RNP plus AAV and RNP plus AAV GFP high groups, respectively (Fig. 3d ). More importantly, we confirmed HBB on-target integration events in human cells sorted from the bone marrow of secondary recipients from RNP plus AAV GFP high experimental groups ( Fig. 3e and Supplementary Fig. 2 ). Collectively, these data confirm that our strategy targets the HBB gene in human HSCs.
We next scaled up the genome-editing process to resemble a more clinically relevant HSPC starting cell number. We electroporated 80 million mobilized peripheral-blood-derived HSPCs with the HBB 
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RNP system, transduced them with either SFFV-GFP or SFFV-tNGFR rAAV6, and then transplanted bulk RNP plus AAV, sorted GFP high and tNGFR high cells (enriched by FACS or magnetic microbeads). At 16 weeks after transplant, all mice displayed engraftment of edited human cells in the bone marrow (Fig. 3f) . In this large-scale procedure, the human cell engraftment of treated cells was equivalent to 'mock' in our previous experiment (Fig. 3b ). Although we observed reductions when comparing editing rates in the input cells to engrafted cells in vivo, the HBB-tNGFR mice showed a lower reduction (12% in vitro versus 7.5% in vivo) than the HBB-GFP mice (10% in vitro versus 1.9% in vivo), suggesting tNGFR might be a better transgene to evaluate editing of HSCs in vivo (Fig. 3g) . Furthermore, mice transplanted with enriched targeted HSPCs displayed human cell-editing frequencies of 10-75% (three mice), with human engraftment levels ranging from 4% to 30% (Fig. 3f, g ). These data suggest that our methodology can be translated to perform large-scale genome editing in HSCs at the HBB locus.
HBB gene correction in SCD HSPCs
We next tested our methodology to correct the disease-causing Glu6Val mutation in CD34 + HSPCs derived from patients with SCD. We first confirmed high frequencies of INDELs ( Fig. 4a ) and homologous recombination using an SFFV-GFP donor (Fig. 4b) at the HBB locus in SCD HSPCs. We then produced a therapeutic rAAV6 donor (corrective SNP donor) designed to revert the Glu6Val mutation, while also introducing silent mutations to prevent Cas9 re-cutting and premature cross over (Extended Data Fig. 8a ). Targeting SCD HSPCs with the corrective SNP donor reverted an average of 50% of the Glu6Val (HbS) alleles to wild-type (HbA) alleles (Fig. 4c) , and analysis of methylcellulose clones showed that an average of 45% of clones had at least one HbA allele (Extended Data Fig. 8b ). We next created an anti-sickling HBB cDNA therapeutic donor (HbAS3; ref. 38) using previously reported strategies 12, 13 of knocking in divergent cDNAs into the gene start codon to preserve endogenous promoter/enhancer function, followed by a clinically relevant promoter (EF1α ) driving tNGFR expression to allow for enrichment of edited cells (Extended Data Fig. 9a ). Using this donor, we targeted an average of 11% of SCD patient-derived HSPCs ( Fig. 4d ) and confirmed seamless integration by in-out PCR (Extended Data Fig. 9b ). Notably, we observed a tNGFR high population as described previously (Fig. 2c) , indicating the ability to enrich SCDcorrected HSPCs early in the culture process. We conclude that our methodology can correct the Glu6Val mutation using two different donor designs.
We next tested whether the HBB-edited SCD HSPCs maintained their erythroid differentiation potential by subjecting tNGFR high and mock HSPCs to a 21-day in vitro erythroid differentiation protocol 39, 40 . Flow cytometric analyses after erythroid differentiation showed a high proportion of GPA + CD45 − CD71 + CD34 − cells, indicating the presence of mature differentiated erythrocytes that express haemoglobin 41 ( Fig. 4e and Extended Data Fig. 10 ). To confirm that adult β -globin (HbA) or HbAS3 mRNA was transcribed from edited HBB alleles, we performed reverse transcription quantitative PCR + human cells in the bone marrow of secondary recipients. e, Gel images of in-out PCR analyses on sorted human cells from secondary recipients to analyse on-target integrations at the 5′ and 3′ ends. Input control (ctrl) PCR was performed on the human CCR5 gene. Positive control is an HSPC sample targeted at HBB with SFFV-GFP-polyA. f, 80 million mobilized peripheral-blood-derived CD34
+ cells were electroporated with HBB RNP and transduced with HBB AAV6s. Bulk HSPCs or HSPCs enriched for targeting (by FACS or bead enrichment) were transplanted into the tail vein of sublethally irradiated mice. Then, 16 weeks after transplant, human cell chimaerism was analysed by flow cytometry (n = number of data points within group). g, Percentage GFP
+ and tNGFR + cells in the human population was analysed by flow cytometry (n = number of data points within group), bars represent median.
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(RT-qPCR) on erythrocytes differentiated from edited SCD HSPCs. Erythrocytes edited with the corrective SNP donor expressed 56% HbA mRNA out of total β -globin mRNA, whereas erythrocytes edited with the cDNA donor (bulk) expressed 20% HbAS3 mRNA (Fig. 4f) . Thus the percentage of HbAS3 mRNA (20%) matched or exceeded the percentage of cells modified by the tNGFR cassette (11%), suggesting functional expression of the AS3 cDNA from the endogenous HBB promoter. Notably, erythrocytes differentiated from enriched tNGFR high HSPCs expressed 70% HbAS3 mRNA, confirming an enrichment of functionally corrected HSPCs.
Discussion
While our data support the idea that HSCs are more resistant to homologous recombination-mediated editing, they also show that it is possible to edit these cells at reasonable frequencies 21 . Enrichment of targeted cells resulted in the removal of most HSCs, leading to an overall eightfold decrease in the total number of HSCs in the transplanted enriched population (Extended Data Fig. 6c ). Even though we transplanted eightfold fewer total HSCs in the enriched population than the non-enriched population (GFP high versus RNP plus AAV), we found that absolute numbers of edited cells in the bone marrow of the mice from the enriched group was on average fivefold higher 16 weeks after transplant (Extended Data Fig. 6c) . Thus, our enrichment strategy not only yields higher frequencies of modified cells in the transplanted mice, but also the absolute number of modified human cells in the mice was higher and can thus ameliorate the problem of inefficient HSC targeting. Recent advances in ex vivo HSC expansion protocols and identification of small molecule drugs, such as UM171 (ref. 42) that expands HSCs, might be combined with our strategy to generate a large and highly enriched population of genome-edited HSCs. Future studies will help to determine whether HSC expansion would be required for clinical translation of our enrichment model.
Our methodology sets the framework for CRISPR-mediated HBB targeting in HSCs that has the power to be translated to the clinic. Although GFP is an unsuitable marker for gene therapy, our enrichment protocol using tNGFR (Figs 2c, 3f, g ) (or other similar signalling-inert cell surface markers) represents a strategy for the next generation of β -haemoglobinopathy therapies that are based on gene editing. These studies show that this methodology can enrich corrected SCD patient-derived HSPCs that can differentiate into erythrocytes that express HBB anti-sickling mRNA from the endogenous HBB promoter. This tNGFR selection strategy has the potential advantage over chemoselection strategies because it avoids exposing edited cells and patients to potentially toxic chemotherapy 13 . The strategy of knocking in a HBB cDNA along with a selectable marker to enrich for modified cells would be applicable to both SCD and almost all forms of β -thalassaemia. Furthermore, because we can efficiently scale up the genome-editing process to clinically relevant starting numbers, future studies will address the development of a current good manufacturing practice (cGMP)-compatible process for editing the HBB locus in HSPCs.
In conclusion, we believe that the presented methodology lays the foundation for CRISPR/Cas9-mediated genome editing therapies not only for the β -haemoglobinopathies, but also for a range of other haematological diseases, and generally advances HSC-based cell and gene therapies.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Information is available in the online version of the paper.
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AAV vector production. AAV vector plasmids were cloned in the pAAV-MCS plasmid (Agilent Technologies) containing inverted terminal repeats from AAV serotype 2. The HBB rAAV6 GFP and tNGFR donor contained promoter, MaxGFP or tNGFR, and BGH polyA. The left and right homology arms for the GFP and tNGFR HBB donors were 540 bp and 420 bp, respectively. The Glu6Val rAAV6 donor contained 2.2 kb of sequence homologous to the sequence upstream of Glu6Val. The nucleotide changes are depicted in Extended Data Fig. 2 . Immediately downstream of the last nucleotide change was 2.2 kb of homologous HBB sequence. HBB cDNA contained same homology arms as GFP and tNGFR donors above except the left homology arm was shortened to end at the sickle mutation. Sequence of full HBB cDNA is depicted in (Extended Data Fig. 9b) . The sickle corrective donor used in the SCD-derived HSPCs in Fig. 4 had a total of 2.4 kb sequence homology to HBB with the SNPs shown in Extended Data Fig. 8a in the centre. scAAV6 carrying the SFFV promoter driving GFP was provided by H.-P. Kiem. AAV6 vectors were produced as described with a few modifications 43 . In brief, 293FT cells (Life Technologies) were seeded at 13 × 10 6 cells per dish in ten 15-cm dishes one day before transfection. One 15-cm dish was transfected using standard PEI transfection with 6 μ g ITR-containing plasmid and 22 μ g pDGM6 (a gift from D. Russell), which contains the AAV6 cap genes, AAV2 rep genes, and adenovirus helper genes. Cells were incubated for 72 h until collection of AAV6 from cells by three freeze-thaw cycles followed by a 45 min incubation with TurboNuclease at 250 U ml −1 (Abnova). AAV vectors were purified on an iodixanol density gradient by ultracentrifugation at 237,000g for 2 h at 18 °C. AAV vectors were extracted at the 60-40% iodixanol interface and dialysed three times in PBS with 5% sorbitol in the last dialysis using a 10K MWCO Slide-A-Lyzer G2 Dialysis Cassette (Thermo Fisher Scientific). Vectors were added pluronic acid to a final concentration of 0.001%, aliquoted, and stored at −80 °C until use. AAV6 vectors were titred using quantitative PCR to measure number of vector genomes as described previously 44 .
CD34
+ haematopoietic stem and progenitor cells. Frozen CD34 + HSPCs derived from bone marrow or mobilized peripheral blood were purchased from AllCells and thawed according to manufacturer's instructions. CD34
+ HSPCs from cord blood were either purchased frozen from AllCells or acquired from donors under informed consent via the Binns Program for Cord Blood Research at Stanford University and used fresh without freezing. CD34
+ HSPCs from patients with SCD were purified within 24 h of the scheduled apheresis. For volume reduction via induced rouleaux formation, whole blood was added 6% Hetastarch in 0.9% sodium chloride injection (Hospira, Inc.) in a proportion of 5:1 (v/v). Following a 60-90-min incubation at room temperature, the top layer, enriched for HSPCs and mature leukocytes, was carefully isolated with minimal disruption of the underlying fraction. Cells were pelleted, combined, and resuspended in a volume of PBS with 2 mM EDTA and 0.5% BGS directly proportional to the fraction of residual erythrocytes-typically 200-400 ml. Mononuclear cells (MNCs) were obtained by density gradient separation using Ficoll and CD34 + HSPCs were purified using the CD34 + Microbead Kit Ultrapure (Miltenyi Biotec) according to manufacturer's protocol. Cells were cultured overnight and then stained for CD34 and CD45 using APC anti-human CD34 (clone 561; Biolegend) and BD Horizon V450 anti-human CD45 (clone HI30; BD Biosciences), and a pure population of HSPCs defined as CD34 bright /CD45 dim were obtained by cell sorting on a FACS Aria II cell sorter (BD Biosciences). All CD34 + HSPCs were cultured in StemSpan SFEM II (StemCell Technologies) supplemented with SCF (100 ng ml ), and StemRegenin1 (0.75 mM). Cells were cultured at 37 °C, 5% CO 2 and 5% O 2 . Electroporation and transduction of cells. The HBB and IL2RG synthetic sgRNAs used were purchased from TriLink BioTechnologies with chemically modified nucleotides at the three terminal positions at both the 5′ and 3′ ends. Modified nucleotides contained 2′-O-methyl-3′-phosphorothioate and the sgRNAs were HPLC-purified. The genomic sgRNA target sequences, with PAM in bold, are: HBB: 5′ -CTTGCCCCACAGGGCAGTAACGG-3′ (refs 45, 46); IL2RG: 5′ -TGGTAATGATGGCTTCAACATGG-3′ . Cas9 mRNA containing 5-methylcytidine and pseudouridine was purchased from TriLink BioTechnologies. Cas9 protein was purchased from Life Technologies. Cas9 RNP was made by incubating protein with sgRNA at a molar ratio of 1:2.5 at 25 °C for 10 min immediately before electroporation. CD34
+ HSPCs were electroporated 1-2 days after thawing or isolation. CD34 + HSPCs were electroporated using the Lonza Nucleofector 2b (program U-014) and the Human T Cell Nucleofection Kit (VPA-1002, Lonza) as we have found this combination to be superior in optimization studies. The following conditions were used: 5 × 10 6 cells ml −1 , 300 μ g ml −1 Cas9 protein complexed with sgRNA at 1:2.5 molar ratio, or 100 μ g ml −1 synthetic chemically modified sgRNA with 150 μ g ml −1 Cas9 mRNA (TriLink BioTechnologies, non-HPLC purified). Following electroporation, cells were incubated for 15 min at 37 °C after which they were added AAV6 donor vectors at an MOI (vector genomes/cell) of 50,000-100,000 and then incubated at 30 °C or 37 °C overnight (if incubated at 30 °C, plates were then transferred to 37 °C) or targeting experiments of freshly sorted HSCs (Extended Data Fig. 5g ), cells were electroporated using the Lonza Nucleofector 4D (program EO-100) and the P3 Primary Cell Nucleofection Kit (V4XP-3024). For the electroporation of 80 million CD34 + HSPCs, the Lonza 4D-Nucleofector LV unit (program DZ-100) and P3 Primary Cell Kit were used. Subsequently, we have found no benefit to the 30 °C incubation and now perform all of our manufacturing at 37 °C. Measuring targeted integration of fluorescent and tNGFR donors. Rates of targeted integration of GFP and tNGFR donors were measured by flow cytometry at least 18 days after electroporation. Targeted integration of a tNGFR expression cassette was measured by flow cytometry of cells stained with APC-conjugated anti-human CD271 (NGFR) antibody (BioLegend, clone: ME20.4). For sorting of GFP high or tNGFR high populations, cells were sorted on a FACS Aria II SORP using the LIVE/DEAD Fixable Blue Dead Cell Stain Kit (Life Technologies) to discriminate live and dead cells according to manufacturer's instructions. Positive selection and enrichment of tNGFR + HSPCs. Positive selection of targeted HSPCs was performed using the CD271 (tNGFR) Microbead Kit (Miltenyi Biotech), according to the manufacturer's instructions 72 h after electroporation. In brief, tNGFR + cells were magnetically labelled with CD271 Microbeads after which the cell suspension was loaded onto an equilibrated MACS column inserted in the magnetic field of a MACS separator. The columns were washed three times, and enriched cells were eluted by removing the column from the magnetic field and eluting with PBS. Enrichment was determined by flow cytometry during culture for 2-3 weeks by FACS analysis every 3 days. Immunophenotyping of targeted HSPCs. Collected wells were stained with LIVE/DEAD Fixable Blue Dead Cell Stain (Life Technologies) and then with anti-human CD34 PE-Cy7 (581, BioLegend), CD38 Alexa Fluor 647 (AT1, Santa Cruz Biotechnologies), CD45RA BV 421 (HI100, BD Biosciences), and CD90 BV605 (5E10, BioLegend) and analysed by flow cytometry. For sorting of CD34
+ HSPCs were stained directly after isolation from blood with anti-human CD34 FITC (8G12, BD Biosciences), CD90 PE (5E10, BD Biosciences), CD38 APC (HIT2, BD Bioscience), and cells were sorted on a FACS Aria II (BD Bioscience), cultured overnight, and then electroporated with HBB RNP and transduced with HBB GFP rAAV6 using our optimized parameters. Measuring targeted integration of the E6V donor. For assessing the allele modification frequencies in samples with targeted integration of the Glu6Val rAAV6 donor, PCR amplicons spanning the targeted region (see Extended Data Fig. 2a) were created using one primer outside the donor homology arm and one inside: HBB_outside 5′ -GGTGACAATTTCTGCCAATCAGG-3′ and HBB_inside: 5′ -GAATGGTAGCTGGATTGTAGCTGC-3′ . The PCR product was gel-purified and re-amplified using a nested primer set (HBB_ nested_fw: 5′ -GAAGATATGCTTAGAACCGAGG-3′ and HBB_nested_rv: 5′ -CCACATGCCCAGTTTCTATTGG-3′ ) to create a 685-bp PCR amplicon (see Extended Data Fig. 2a ) that was gel-purified and cloned into a TOPO plasmid using the Zero Blunt TOPO PCR Cloning Kit (Life Technologies) according to the manufacturer's protocol. TOPO reactions were transformed into XL-1 Blue competent cells, plated on kanamycin-containing agar plates, and single colonies were sequenced by McLab by rolling circle amplification followed by sequencing using the following primer: 5′ -GAAGATATGCTTAGAACCGAGG-3′ . For each of the six unique CD34 + donors used in this experiment, 100 colonies were sequenced. Additionally, 100 colonies derived from an AAV-only sample were sequenced and detected no integration events. Measuring INDEL frequencies. INDEL frequencies were quantified using the TIDE software 47 (tracking of indels by decomposition) and sequenced PCR products obtained by PCR of genomic DNA extracted at least 4 days after electroporation as previously described 14 . Methylcellulose CFU assay. The CFU assay was performed by FACS sorting of single cells into 96-well plates containing MethoCult Optimum (StemCell Technologies) 4 days after electroporation and transduction. After 12-16 days, colonies were counted and scored based on their morphological appearance in a blinded fashion. Genotyping of methylcellulose colonies. DNA was extracted from colonies formed in methylcellulose from FACS sorting of single cells into 96-well plates. In brief, PBS was added to wells with colonies, and the contents were mixed and transferred to a U-bottomed 96-well plate. Cells were pelleted by centrifugation at 300g for 5 min followed by a wash with PBS. Finally, cells were resuspended in 25 μ l QuickExtract DNA Extraction Solution (Epicentre) and transferred to PCR plates, which were incubated at 65 °C for 10 min followed by 100 °C for 2 min. Integrated or non-integrated alleles were detected by PCR. For detecting HBB GFP integrations at the 3′ end, two different PCRs were set up to detect integrated (one primer in insert and one primer outside right homology arm) and non-integrated alleles (primer in each homology arm), respectively (see Extended Data Fig. 4a) . HBB_int_fw: 5′ -GTACCAGCACGCCTTCAAGACC-3′ , HBB_int_rv: 5′ -GATCCTGAGACTTCCACACTGATGC-3′ , HBB_no_ int_fw: 5′ -GAAGATATGCTTAGAACCGAGG-3′ , HBB_no_int_rv: 5′ -CCACATGCCCAGTTTCTATTGG-3′ . For detecting HBB tNGFR integrations at the 5′ end, a 3-primer PCR methodology was used to detect the integrated and non-integrated allele simultaneously (see Extended Data Fig. 4d ). HBB_outside_5′ Arm_fw: 5′-GAAGATATGCTTAGAACCGAGG-3′, SFFV_rev: 5′-ACCGCAGATATCCTGTTTGG-3′, HBB_inside_3′ Arm_rev: 5′-CCACATGCCCAGTTTCTATTGG-3′. Note that for the primers assessing nonintegrated alleles, the Cas9 cut site is at least 90 bp away from the primer-binding sites and since CRISPR/Cas9 generally introduces INDELs of small sizes, the primer-binding sites should only very rarely be disrupted by an INDEL.
Transplantation of CD34
+ HSPCs into NSG mice. For in vivo studies, 6 to 8 week-old NSG mice were purchased from the Jackson laboratory (Bar Harbour). The experimental protocol was approved by Stanford University's Administrative Panel on Laboratory Animal Care. For transplant data in Fig. 3a-c , sample sizes were not chosen to ensure adequate power to detect a pre-specified effect size. Four days after electroporation/ transduction or directly after sorting, 500,000 cells (or 100,000-500,000 cells for the GFP high group) were administered by tail-vein injection into the mice after sub-lethal irradiation (200 cGy) using an insulin syringe with a 27 gauge × 0.5 inch (12.7 mm) needle. For transplant data in Fig. 3f , g, three days after electroporation, 400,000-700,000 bulk HSPCs or HSPCs enriched for targeting (FACS or bead-enrichment) were transplanted as described above. Mice were randomly assigned to each experimental group and evaluated in a blinded fashion. For secondary transplants, human cells from the RNP plus AAV group were pooled and CD34
+ cells were selected using a CD34 bead enrichment kit (MACS CD34 MicroBead Kit UltraPure, human, Miltenyi Biotec), and finally cells were injected into the femurs of female secondary recipients (3 mice total). Because GFP high mice had low engraftment, they were not CD34 + -selected, but total mononuclear cells were filtered, pooled, and finally injected into the femur of two secondary recipients. Assessment of human engraftment. At week 16 after transplantation, mice were euthanized, mouse bones (2× femur, 2× tibia, 2× humerus, sternum, 2× pelvis, spine) were collected and crushed using mortar and pestle. MNCs were enriched using Ficoll gradient centrifugation (Ficoll-Paque Plus, GE Healthcare) for 25 min at 2,000g, room temperature. Cells were blocked for nonspecific antibody binding + HLA-ABC + cells. Parts of the mouse bone marrow were used for CD34-enrichment (MACS CD34 MicroBead Kit UltraPure, human, Miltenyi Biotec) and the presence of human HSPCs was assessed by staining with anti-human CD34 APC (8G12, BD Biosciences), CD38 PE-Cy7 (HB7, BD Biosciences), CD10 APC-Cy7 (HI10a, BioLegend), and anti-mouse CD45.1 PE-Cy5 (A20, eBioScience) and analysed by flow cytometry. The estimation of the total number of modified human cells in the bone marrow at week 16 after transplant was calculated by multiplying the percentage engraftment with the percentage GFP + cells among engrafted cells. This number was multiplied by the total number of MNCs in the bone marrow of a NSG mouse (1.1 × 10 8 per mouse) to give the total number of GFP + human cells in the total bone marrow of the transplanted mice. The total number of MNCs in the bone marrow of a NSG mouse was calculated by counting the total number of MNCs in one femur in four NSG mice. The total number of MNCs in one mouse was then calculated assuming one femur is 6.1% of the total marrow as found previously 48 .
Differentiation of CD34
+ HSPCs into erythrocytes in vitro. SCD patient-derived HSPCs were cultured in three phases following targeting at 37 °C and 5% CO 2 in SFEM II media according to previously established protocols 39, 40 . Media was supplemented with 100 U ml −1 penicillin/streptomycin, 2 mM l-glutamine, 40 μ g ml
lipids, 100 ng ml −1 SCF, 10 ng ml −1 IL-3 (PeproTech), 0.5 U ml −1 erythropoietin (eBiosciences), and 200 μ g ml −1 transferrin (Sigma Aldrich). In the first phase, corresponding to days 0-7 (day 0 being day 4 after electroporation), cells were cultured at 10 5 cells ml
. In the second phase, corresponding to days 7-11, cells were maintained at 10 5 cells ml −1 and erythropoietin was increased to 3 U ml −1 . In the third and final phase, days 11-21, cells were cultured at 10 6 cells ml
with 3 U ml −1 of erythropoietin and 1 mg ml −1 of transferrin. Erythrocyte differentiation of edited and non-edited HSPCs was assessed by flow cytometry using the following antibodies: hCD45 V450 (HI30, BD Biosciences), CD34 FITC (8G12, BD Biosciences), CD71 PE-Cy7 (OKT9, Affymetrix), and CD235a PE (GPA) (GA-R2, BD Biosciences). Assessment of mRNA levels in differentiated erythrocytes. RNA was extracted from 100,000-250,000 differentiated erythrocytes between days 16-21 of erythroid differentiation using the RNeasy Mini Kit (Qiagen) and was DNase-treated with RNase-Free DNase Set (Qiagen). cDNA was made from 100 ng RNA using the iScript Reverse Transcription Supermix for RT-qPCR (Bio-Rad). Levels of HbS, HbA (from corrective SNP donor), and HbA-AS3 (anti-sickling HBB cDNA donor) were quantified by qPCR using the following primers and FAM/ZEN/ IBFQ-labelled hydrolysis probes purchased as custom-designed PrimeTime qPCR Assays from IDT: HbS primer (fw): 5′ -TCACTAGCAACCTCAAACAGAC-3′, HbS primer (rv): 5′ -ATCCACGTTCACCTTGCC-3′ , HbS probe: 5′ -TAACG GCAGACTTCTCCACAGGAGTCA-3′ , HbA primer (fw): 5′ -TCACTAGCAACCT CAAACAGAC-3′ , HbA primer (rv): 5′ -ATCCACGTTCACCTTGCC-3′ , HbA probe: 5′ -TGACTGCGGATTTTTCCTCAGGAGTCA-3′ , HbAS3 primer fw: 5′ -GTGTATCCCTGGACACAAAGAT-3′ , HbAS3 primer (rv): 5′ -GGGC TTTGACTTTGGGATTTC-3′ , HbAS3 probe: 5′ -TTCGAAAGCTTCGGC GACCTCA-3′ . Primers for HbA and HbS are identical, but probes differ by six nucleotides, and therefore it was experimentally confirmed that these two assays do not cross-react with targets. To normalize for RNA input, levels of the reference gene RPLP0 was determined in each sample using the IDT predesigned RPLP0 assay (Hs.PT.58.20222060). qPCR reactions were carried out on a LightCycler 480 II (Roche) using the SsoAdvanced Universal Probes Supermix (BioRad) following manufacturer's protocol and PCR conditions of 10 min at 95 °C, 50 cycles of 15 s at 95 °C and 60 s at 58 °C. Relative mRNA levels were determined using the relative standard curve method, in which a standard curve for each gene was made from serial dilutions of the cDNA. The standard curve was used to calculate relative amounts of target mRNA in the samples relative to levels of RPLP0. Data availability. The authors declare that the data supporting the findings of this study are available within the paper. 
HSPCs. a, CD34
+ HSPCs were transduced with a scAAV6 expressing GFP from an SFFV promoter at multiplicities of infections (MOIs) of 10,000 or 100,000 viral genomes (vg) per cell for 48 h and then analysed for percentage GFP + expression by flow cytometry using a non-transduced sample to set the GFP + gate at < 0.1% GFP + cells. scAAV was used because it eliminates second-strand synthesis as a confounder of actual transduction. Results are from two independent experiments from at least two donors and error bars represent s.d. ABM, adult bone marrow; CB, cord blood; mPB: mobilized peripheral blood. b, CD34
+ HSPCs were electroporated with the HBB CRISPR system (mRNA or RNP delivery) or without (AAV only), and then transduced with HBB rAAV6 donor vectors at an MOI of 100,000 vg per cell. Day 4 after electroporation, cells were analysed by flow cytometry and live cells were gated in high forward scatter (FSC) and low side scatter (SSC). Percentage of cells in FSC/SSC gate (that is, percentage viability) is shown relative to that of mock-electroporated cells. Each data point represents a unique CD34 + HSPC donor. c, Top, sgRNA target sequences at the HBB on-target site and a highly complementary off-target site (Chr9:101833584-101833606) are shown. PAM sequences are underlined and red sequence highlights the three mismatches of the off-target site. Bottom, HSPCs were electroporated with either the mRNA or RNP-based CRISPR system, and 4 days post electroporation genomic DNA was extracted and analysed for INDEL frequencies using TIDE at the on-target HBB and the offtarget site. Results are shown as the ratio of on-to off-target activity highlighting the increased specificity of the RNP system. Averages from three different CD34 + HSPC donors are shown and error bars represent s.e.m. * * P < 0.01, unpaired Student's t-test. d, INDEL frequencies for the data presented in c. * P < 0.05, paired Student's t-test. e, Representative FACS plots showing stable GFP rates at day 18 after electroporation in donor-nuclease mismatch experiments. Mismatching nuclease and donor (red box) leads to infrequent end-capture events compared to on-target homologous recombination events observed with matched nuclease and homologous rAAV6 donor (green box). HSPCs were electroporated with 15 μ g Cas9 mRNA and either HBB or IL2RG 2′-O-methyl-3′-phosphorothioate-modified sgRNA, then transduced with HBB-GFP rAAV6 donor followed by 18 days of culture. f, End-capture experiments were performed in three replicate experiments each in three unique CD34 + HSPC donors. ns (not significant) = P ≥ 0.05, paired Student's t-test. Activity of the IL2RG CRISPR was confirmed by quantification of INDELs at the IL2RG target site using TIDE analysis. Figure 2 | Schematic of targeting rAAV6 Glu6Val homologous donor to the HBB locus. a, The human HBB locus on chromosome 11 is depicted at the top of the schematic and consists of three exons (black boxes) and two introns. The rAAV6 Glu6Val donor includes the Glu to Val mutation at codon 6, which is the amino acid change causing SCD. Other SNPs (all SNPs are capitalized) were introduced to PAM site (blue) and sgRNA-binding site (bold) to prevent re-cutting following homologous recombination in HSPCs. To analyse targeted integration frequencies in HSPCs, a two-step PCR was performed. First, a 3,400-bp in-out PCR (green) was performed followed by a nested 685-bp PCR (purple) on a gel-purified fragment from the first PCR. This second PCR fragment was cloned into TOPO vectors, which were sequenced to determine the allele genotype (wild type, INDEL or homologous recombination). b, The sequence of a wild-type HBB allele aligned with the sequence of an allele that has undergone homologous recombination. c, Representative INDELs from the data represented in Fig. 1d . The HBB reference sequence is shown in green. + CD10 − CD38 − populations (note that CD10 was included as a negative discriminator for immature B cells). c, Collective data from the analysis of GFP + cells in the human CD34 + CD10 − population from the RNP plus AAV (n = 11) and RNP plus AAV GFP high (n = 6) experimental groups. For the RNP plus AAV GFP high group, cells from all six mice were pooled before analysis and thus, no error bar is available. Error bar on RNP group represents s.e.m.
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